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In 2005, 224 patients received adjuvant/neoadjuvant chemotherapy for breast cancer in a single institution according to daily
practices. Regimens consisted of epirubicin-based chemotherapy (FEC100, four or six cycles), or three cycles of FEC100 followed by
three cycles of docetaxel. An absolute blood count was carried out every 3 weeks, 1–3 days before planned chemotherapy cycle.
Overall, 1238 cycles were delivered. An absolute neutrophil count (ANC) o1.5 10
9l
 1 before planned chemotherapy was found
in 171 cycles. Of these, 130 cycles (76%) were delivered as planned regardless of whether ANC levels recovered, and 41 (24%) were
delayed. None of these patients developed a febrile neutropaenia. Haematopoietic support (granulocyte colony-stimulating factor
(G-CSF)) was required in 12 cycles. We found that the majority of patients with an ANC o1.5 10
9l
 1 before planned
chemotherapy received planned doses, without complications and need for G-CSF.
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The adjuvant treatment of breast cancer has evolved during the last
30 years. In the middle of the 1970s, Bonadonna et al (1995)
pioneered the use of adjuvant chemotherapy by establishing the
contribution of the CMF regimen (cyclophosphamide, methotrex-
ate, and fluorouracil) to improvements in disease-free (DFS) and
overall survival (OS). Successive overviews of the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) (2005) have
highlighted several trends, which have been reinforced over time:
polychemotherapy is superior to monochemotherapy, anthra-
cycline-based chemotherapy is superior to CMF, and the relative
benefit of chemotherapy is independent of menopausal status and
axillary lymph nodes involvement. Consequently, the anthracy-
clines are considered pivotal for adjuvant chemotherapy. Although
no benefit of an increase in cyclophosphamide doses has been
found (Smith et al, 2003), it has been shown that doxorubicin
was more effective when used at a dose higher than 30mgm
 2
(Budman et al, 1998), and that an increase in epirubicin dose
intensity significantly improved DFS and OS (Bonneterre et al,
2005). Therefore, anthracycline doses were gradually increased,
especially for the treatment of node-positive breast cancer.
Presently, the use of anthracycline-based regimens extends to
high-risk, node-negative patients. Taxanes (paclitaxel and
docetaxel) were introduced in the 1990s, and their role in the
treatment of node-positive early breast cancer has been widely
investigated. To date, major randomised trials have shown a
significant improvement in DFS (Citron et al, 2003; Henderson
et al, 2003; Mamounas et al, 2005; Martin et al, 2005; Roche et al,
2006) and OS (Citron et al, 2003; Henderson et al, 2003; Martin
et al, 2005; Roche et al, 2006), when a taxane is added to an
anthracycline in sequential, concomitant, or dose-dense regimens.
Both the increase in anthracycline doses and introduction of
taxanes have increased the incidence of myelotoxicity, resulting in
a higher incidence of neutropaenia, and then an increased risk of
febrile neutropaenia and life-threatening infections. According to
the rules established by successive randomised trials, it is a current
practice to postpone the next cycle for a week and/or to use lower
drug doses below an accepted neutrophil count of 1.5 10
9l
 1.
This is detrimental to maintaining the dose intensity, and
consequently, the efficacy of planned regimens (Weiss et al,
1987; Wood et al, 1994; Bonadonna et al, 1995; Budman et al, 1998;
Chirivella et al, 2006). According to the criteria defined by
Bonadonna et al (1995), it is assumed that chemotherapy dose
intensity below 85% of the planned dose significantly decreases the
treatment efficacy. To counterbalance the consequences of a low
neutrophil count, the use of granulocyte colony-stimulating factors
(G-CSFs) has been extended, limiting the risk of infection and
maintaining the chemotherapy dose intensity if its reduction may
compromise efficacy (Smith et al, 2006).
However, a systematic postponement of chemotherapy of 1 week
when the neutrophil count is below 1.5 10
9l
 1, or the use of
G-CSF are often practised in clinical trials, they are not always
consistent with community practices. Thereby, we conducted a
retrospective analysis of non-selected breast cancer patients
receiving adjuvant or neoadjuvant 100-mgm
 2 epirubicin-based
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sregimens with or without sequential docetaxel. The purpose of this
analysis was to evaluate the feasibility of those regimens in daily
practices, and the real incidence of treatment delays and use of
haematopoietic support.
PATIENTS AND METHODS
Study population and treatment regimens
All non-metastatic breast cancer patients who had received
adjuvant or neoadjuvant chemotherapy outside clinical trials in
2005 were reviewed in our institution (Institut Bergonie ´, Bordeaux,
France). The data reviewed and recorded in the hospital file were
absolute neutrophil count (ANC) measured at baseline, before next
chemotherapy cycle and subsequently in case of cycle delay, date
of chemotherapy administration and dose, prescription of G-CSF,
and toxicities occurring between cycles. The only exclusion
criterion was patients treated in neoadjuvant/adjuvant clinical
trials.
Planned treatment regimens consisted of FEC100 (fluorouracil
500mgm
 2, epirubicin 100mgm
 2, cyclophosphamide 500mgm
 2
day 1, every 21 days) for four or six cycles according to axillary
lymph nodes involvement, or three cycles of FEC100 followed by
three cycles of docetaxel (D) 100mgm
 2 (day 1, every 21 days)
(Roche et al, 2006). In case of overexpression and/or amplification
of HER-2, patients received trastuzumab started concurrently with
docetaxel (D). Adjuvant endocrine therapy and radiotherapy were
started at the end of chemotherapy when indicated.
Data analysis
According to the standard practices of our institution, a blood
count is carried out (outside the hospital) the day before the
planned chemotherapy infusion (contingently Friday or Saturday
when treatment was planned on Monday). The decision to deliver
chemotherapy, to control ANC at the time of patient’s hospital
entry, or to postpone the next chemotherapy cycle depends on
ANC, perceived risk of infectious events, and oncologist experi-
ence. Qualitative data were presented as a percentage, and ANC
quantitative data were described using mean, median, s.d., and
range. The relative dose intensity (RDI) was calculated based on
the ratio of the drug doses actually delivered in the originally
expected time over the expected dose in the expected time
(Ferreira Filho et al, 2002).
RESULTS
Patient characteristics and treatment protocols
During the year 2005, 224 non-metastatic breast cancer patients
were treated in this setting. The median age was 49 years (range:
26–72 years) with 37 patients (16.5%) older than 60 years, and
three (1.3%) older than 70 years. Four chemotherapy regimens
were delivered: (1) four cycles of FEC100; (2) six cycles of FEC100;
(3) three cycles of FEC100 followed by three cycles of docetaxel
(D); (4) three cycles of FEC100 followed by three cycles of
docetaxel (D) plus trastuzumab. Noteworthy, 90% of FEC100-D
regimens were initiated after March 2005 consequently to the
results of PACS 01 trial (Roche et al, 2006). The distribution of
each regimen is summarised in Table 1. Sixty-two patients (27.7%)
received chemotherapy in neoadjuvant setting.
Planned doses of chemotherapy were well respected (Table 2).
The treatment planned was changed for eight patients (3.6%): six
with FEC100-D regimen (severe cutaneous toxicity in three,
patient’s refusal in two, and hypersensitivity in one); and two
with FEC100 because of pancytopaenia in one and digestive
toxicity in the other. Forty-six cycles (4.5%) were delayed for more
than 7 days in 35 patients (15.6%). In half of the cases, this delay
was the result of neutropaenia. A 20–25% dose reduction was
applied in 19 cycles (1.9%) and nine patients (4%): five patients
received FEC100-D, and four received FEC100 (Table 3).
Absolute neutrophil count, cycle delay, and relative dose
intensity
An overall number of 1238 cycles have been administered. Among
the 1007 cycles delivered between the second and the sixth courses,
ANCs were available in 995 cases (98.8%). The ANCs have been
measured on day 21 in 510 cases (51.3%), on day 20 in 136 cases
(13.7%), on day 19 in 41 cases (4.1%), and on day 18 in 22 cases
(2.2%). In 220 cases (22.1%), ANC was measured at the time of
hospital entry for chemotherapy on day 22 or 23. The ANC was
measured on days 24–29 in 76 cases (7.6%) because of a cycle
delay related to non-haematological toxicities or patient conve-
nience. An ANC o1.5 10
9l
 1 was reported in 171 cases (17.2%)
secondary to 16 cases out of 220 having an ANC measured on day
22 or 23 (7.2%), 89 out of 510 ANC on day 21 (17.5%), 44 out of
136 ANC on day 20 (32.4%), 15 out of 41 ANC on day 19 (36.6%),
and 7 out of 22 ANC on day 18 (31.8%). This situation occurred
in 169 cycles after FEC100 out of 791 (21.4%), and in 2 out of
216 cycles (0.9%) after docetaxel (D). Among cycles with ANC
o1.5 10
9l
 1, three situations were possible (Figure 1). (1) The
next chemotherapy cycle was delivered without postponement and
no need for a new ANC in 69 cases (40.3%): in seven cases (10.1%)
the ANC was below 1 10
9l
 1, and in nine cases (13%) the ANC
has been measured 3 or 4 days before treatment. (2) A repeat of
ANC was measured at the time of patient’s hospital entry within 2
days in 70 cases (40.9%). (3) Thirty-two cycles required a repeat of
ANC more than 2 days after the first measurement. A new repeat
was performed at a mean interval of 4.8 days (range: 3–8 days)
showing a neutrophil recovery in 100% of the cases and allowing
chemotherapy administration.
Table 1 Distribution of treatment protocols among the 224 selected
breast cancer patients
4 FEC100 6 FEC100 3 FEC100-3D 3 FEC100-3D+T
Patients, n (%) 54 (24.1) 59 (26.3) 94 (42.0) 17 (7.6)
Chemotherapy,
n( % )
Adjuvant 53 (98.1) 37 (62.7) 63 (67.0) 9 (52.9)
Neoadjuvant 1 (1.9) 22 (37.3) 31 (33.0) 8 (47.1)
Age, years
Median (range) 49 (30–72) 50 (29–68) 50 (26–69) 48 (31–72)
460 years,
n (%)
5 (9.2) 9 (15.2) 20 (21.3) 3 (17.6)
470 years,
n (%)
1 (1.8) 0 (0.0) 0 (0.0) 2 (11.8)
D¼docetaxel 100mgm
 2 every21days;FEC100¼fluorouracil 500mgm
 2, epirubicin
100mgm
 2, cyclophosphamide 500mgm
 2 every 21 days; T¼trastuzumab.
Table 2 Relative dose intensity according to treatment protocol
4 FEC100 6 FEC100 3 FEC100-3D (±T)
Number of patients 54 59 111
RDI, median (range) 99% (75–101) 97% (76–102) 99% (68–102)
RDI495%, n (%) 41 (76) 42 (71) 89 (80)
RDIo85%, n (%) 4 (7) 4 (7) 6 (5)
D¼docetaxel 100mgm
 2 every 21 days; FEC100¼fluorouracil 500mgm
 2,
epirubicin 100mgm
 2, cyclophosphamide 500mgm
 2 every 21 days; RDI¼relative
dose intensity; T¼trastuzumab.
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sOverall, 130 cycles (76%) were delivered as planned with or
without a repeat of ANC, and 41 (24%) has to be delayed because
of neutropaenia. In case of ANC o1.5 10
9l
 1, the subsequent
blood counts showed that neutrophil recovery occurred in 75%
of cases (39/52) on day þ1, in 83% (15/18) on day þ2, and in
100% (32/32) from days þ3t oþ8. When the repeat of ANC has
been measured within 48h following an ANC o1.5 10
9l
 1, the
neutrophil recovery was 100% (n¼37) if ANC41 10
9l
 1, and
70% (n¼33) if ANCo1 10
9l
 1.
The RDI of each protocol is described in Table 2. An RDI higher
than 95% was reached in 172 patients (76.8%), whereas 14 patients
(6.2%) have received lower than 85% of the planned dose. The
decrease in RDI was the result of haematologic toxicity or
infectious complications in one-third of cases. Other reasons were
cycle delays related to patients or hospital convenience.
Safety profile and haematopoietic support
Among the 76 chemotherapy cycles delivered in spite of an ANC
o1.5. 10
9l
 1, no case of infections were reported. On the other
hand, 14 cases of febrile neutropaenia were reported, of which 10
occurred consequently to the first cycle, and four between the
second and the sixth cycles with an ANC at the initiation of
chemotherapy of 3.51, 3.53, 6.09, and 7.83 10
9l
 1, respectively. A
secondary prophylaxis with G-CSF was required in eight patients
(3.6%) because of febrile neutropaenia in three cases and
prevention of neutropaenia-related cycle delay in five cases. The
main toxicities of treatment are presented in Table 3. Besides,
seven patients (3.1%) experienced a severe cutaneous toxicity
related to docetaxel. No toxic death or persistent toxicity was
registered.
DISCUSSION
Over time, growing evidence has emerged that chemotherapy RDI is
a key principle of adjuvant chemotherapy efficacy. The long-term
follow-up results of the CMF trial, conducted by Bonadonna et al
(1995), showed that the 20-year DFS of patients was 52% when they
had received at least 85% of the planned dose versus 27% if the dose
was below this rate. This has been confirmed by other retrospective
studies using either CMF (Mayers et al, 2001) or anthracycline-
based regimens (Chirivella et al, 2006). Moreover, numerous
retrospective studies suggested that early breast cancer patients
who experienced the greater myelosuppression related to adjuvant
chemotherapy have a trend towards a better outcome (Saarto et al,
1997; Colleoni et al, 1998; Poikonen et al, 1999; Mayers et al, 2001;
Cameron et al, 2003). Additionally, prospective studies demon-
strated that an increase in chemotherapy RDI resulted in an
improvement of DFS and OS (Budman et al, 1998; Citron et al, 2003;
Bonneterre et al, 2005). In spite of these clear data, several
retrospective analyses evaluating adjuvant chemotherapy RDI in
daily practices have shown a significant decrease in RDI,
irrespective of country and chemotherapy regimen (Link et al,
2001; Morrow et al, 2002; Ottevanger et al, 2002; Leonard et al, 2003;
Lyman et al, 2003; Schaapveld et al, 2004; Chirivella et al, 2006;
Shayne et al, 2006). Among these analyses, 20–30% of patients
received less than 85% of pre-planned chemotherapy schedule.
However, the percentage of patients receiving o85% of the dose has
been gradually reduced. Indeed, there was a 26% decrease in dose
reduction o85% across successive analyses of a same report
(Lyman et al,2 0 0 3 ;S h a y n eet al, 2006). One could argue that
physicians and quality of care control have assumed that the
criterion of Bonadonna et al (1995) with a cutoff value of 85% as
efficacy predictor was major for the management of early breast
cancer patients (Budman et al, 1998; Mayers et al, 2001; Morrow
et al, 2002; Ottevanger et al, 2002; Shayne et al,2 0 0 6 ) .
For the first use of FEC100 regimen in the French Adjuvant
Study Group (FASG) 05 trial, conducted between 1990 and 1993,
no prophylactic use of G-CSF was permitted, and an AN-
Co2 10
9l
 1 led to a treatment interruption of at least 1 week
(Bonneterre et al, 2005). Thereby, among the 268 patients who
received the FEC100 regimen, the mean RDI was 86.1%, and seven
cases (2.6%) of febrile neutropaenia occurred. More recently, in
the PACS 01 trial initiated in 1997 and comparing 6 FEC100 to 3
FEC100-3D, the mandatory ANC for a subsequent cycle delivery
ANC<1.5×109 l–1
n=171 cycles 
Administration of CT
without control 
n=69 cycles 
Control at outpatient arrival
(2 days)
n=70 cycles 
Med: 0.93×109 l–1 (0.35–1.34) Med: 0.76×109 l–1 (0.25–1.33)
Med: 1.30×109 l–1 (0.66–1.49)
CT
ANC<1.5×109 l–1
n=16 cycles 
ANC>1.5×109 l–1
n=54 cycles 
CT CT postponed
Control >2 days 
n=32 cycles 
Mean delay for control=4.8 days
ANC>1.5×109 l–1 = 100%
CT
ANC>12×109 l–1
n=7 cycles 
ANC<1.2×109 l–1
n=9 cycles 
Figure 1 Flow chart of chemotherapy administration according to absolute neutrophil count below 1.5 10
9l
 1. ANC, absolute neutrophil count; CT,
chemotherapy. Med: median ANC (min-max).
Table 3 Haematologic toxicities of treatment
4 FEC100 6 FEC100 3 FEC100-3D (±T) Total
Number of patients 54 59 111 224
Patients with toxicity 11 18 22 51
Hospitalisation
a 10 4 5
Changes in treatment
plan
b
11 6 8
Cycle delay X7 days 9 16 21 46
Dose reduction X15% 0 4 5 9
G-CSF 2 5 1 8
D¼docetaxel 100mgm
 2 every 21 days; FEC100¼fluorouracil 500mgm
 2,
epirubicin 100mgm
 2, cyclophosphamide 500mgm
 2 every 21 days; G-CSF¼
granulocyte colony-stimulating factor; T¼trastuzumab.
aFebrile neutropaenia (n¼3),
cutaneous toxicity (n¼1), and acute colitis (n¼1).
bSuppression of one cycle of FEC
because of pancytopaenia (n¼1), suppression of one or two cycles of D because of
hypersensitivity (n¼1) or patient willingness (n¼2), replacement of one cycle of
FEC by D because of severe emesis (n¼1), replacement of one or two cycles of D
by FEC because of cutaneous toxicity (n¼3).
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swas lowered to 1.5 10
9l
 1, whereas an ANCo1.5 10
9l
 1
required the use of G-CSF for all subsequent cycles (Roche et al,
2006). In this trial, the median RDI was 98 and 99%, respectively,
whereas G-CSF was prescribed in 27% of the patients receiving
FEC100 compared with 22% of those receiving docetaxel.
Noteworthy, only 8.4 and 11.2% of patients, respectively, developed
a febrile neutropaenia, showing that the prescription of G-CSF aimed
predominantly to facilitate neutrophil recovery and to maintain RDI
rather than to prevent secondary infections. The comparison between
these two randomised trials highlights that changes in treatment
modalities lead to a 12% increase of RDI, whereas the use of G-CSF is
multiplied by 35 (Bonneterre et al, 2005; Roche et al, 2006).
One of the major reasons identified for a reduction in
chemotherapy doses was neutropaenia (Silber et al, 1998; Link
et al, 2001). Indeed, chemo-induced neutropaenia are often
controlled by dose reductions, or cycle delays, which may
compromise the disease outcome. The most frequently used option
is the use of G-CSF, according to the International Oncology
guidelines, which consider that a G-CSF prophylaxis can be used to
maintain adequate dose intensity for disease outcome (Greil and
Jost, 2005; Aapro et al, 2006; Smith et al, 2006; Lyman and Kleiner,
2007). However, the guidelines are a little variable on their
indications for use of haematopoietic support. For instance, Smith
et al (2006) did not recommend use maintaining dose intensity for
adjuvant breast cancer chemotherapy, as they considered that there
is no evidence that a slight decrease in dose or a slight prolongation
of dose interval worsens outcome. Moreover, an extension in the
use of G-CSF may be counterbalanced by long-term side effects.
First, some data suggested that G-CSF might worsen anaemia in
patients receiving adjuvant chemotherapy (Papaldo et al, 2006). Of
major concerns, an increased risk of secondary acute myeloblastic
leukaemia (AML) and myelodysplastic syndrome (MDS) has been
recently reported (Smith et al, 2003; Praga et al, 2005; Veyret et al,
2006; Hershman et al, 2007; Le Deley et al, 2007). The relationship
between AML/MDS because of haematopoietic support must be
cautiously interpreted because of the accumulation of confusing
factors. Meanwhile, G-CSF use should not be assumed to be risk
free. The G-CSF could be more cost-effectively and cautiously
applied if targeted to patients with identified risk factors of febrile
neutropaenia instead of severe neutropaenia (Borg et al, 2004).
Another option could be a prophylactic use of antibiotics (Schro ¨der
et al, 1999). However, it remains controversial as recently
illustrated by comments following publication of a randomised
study on this topic (Cullen et al, 2005, and correspondence).
Another means to maintain RDI of adjuvant chemotherapy may
be to lower ANC threshold for administration of chemotherapy.
Our experience showed that no infectious complications occurred
among 76 patients who received a full-dose schedule despite an
ANC o1.5 10
9l
 1. This observation is in agreement with data
reported in the literature showing that an ANC o1.5 10
9l
 1 at
the onset of chemotherapy was not convincingly associated with an
increased risk of febrile neutropaenia (Greil and Jost, 2005).
Previously, the National Surgical Adjuvant Breast and Bowel
Project B-15 and B-16 trials showed that the reintroduction of
chemotherapy with ANC ranging between 1.0 and 1.5 10
9l
 1 was
possible (Fisher et al, 1990a,b). In a recent retrospective study
involving Hodgkin’s lymphoma patients, the ABVD (adriamycin,
bleomycin, vinblastine, and dacarbazine) administration irrespec-
tive of granulocyte counts allowed the treatment to be given at full
dose without delays or significant number of infective episodes
(Boleti and Mead, 2007). Authors concluded that they found no
increased risk of severe infections despite the vast majority of
patients experiencing at least one episode of grades 3–4
neutropaenia, of which one-third had at least one episode of
grade 4 toxicity. In the present analysis, neutrophil recovery
occurred always around the twenty-first day, and did not justify a
postponement of 8 days. We could conclude that the 7-day median
cycle delay is a consequence of daily practices based on convenient
factors. The reduction of the delay by re-evaluating blood counts
after 2–3 days would probably improve RDI.
However, our results must be cautiously considered. First, in our
standard practices, an adjuvant chemotherapy was not prescribed
to patients older than 70 years outside clinical trials, taking into
account that no significant benefits were found in EBCTCG
overviews (Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), 2005). This standard could be debatable according to
recent results of randomised trials showing a significant reduction
in breast cancer recurrence and mortality with adjuvant
chemotherapy for elderly patients (Fargeot et al, 2004; Muss
et al, 2005). On the other hand, the advanced age has been found
to be an independent prognostic factor of decrease in RDI
(Bonadonna et al, 1995; Crivellari et al, 2000; Lyman et al, 2003;
Shayne et al, 2006), and to be associated with a higher rate of
neutropaenic complications (Crivellari et al, 2000; Dees et al, 2000;
Muss et al, 2007), of which clinical consequences were more severe
(Balducci and Yates, 2000). Second, the 3 FEC100-3D regimen may
be a favourable schedule for re-treatment with a low ANC as
docetaxel (D) induces deep but short neutropaenia always
corrected on day 22. A re-treatment at ANC of 1 10
9l
 1 or less
may not be applied with other adjuvant regimens that affect more
strongly bone marrow. It has been found that doxorubicin–CMF
regimen necessitated further delays subsequently to the first
episode in the absence of dose reduction, dose delay, or G-CSF
administration (Rivera et al, 2003). Across classical chemotherapy
regimens used in clinical practice (Canadian CEF, oral or
intravenous CMF, AC), 42% of patients experienced at least one
neutropaenic event, and 72% of them developed additional events
in subsequent cycles (Chang, 2000). When docetaxel was used
concurrently with fluorouracil and cyclophosphamide (TAC) plus
systematic antibiotic prophylaxis, the incidence of grades 3–4
neutropaenia on day 21 was 65%, with 24% of febrile neutropaenia
requiring subsequent use of G-CSF (Martin et al, 2005).
In conclusion, this analysis confirms that four–six cycles of
FEC100 and three FEC100-3D regimens are feasible in the general
population without severe toxicity. Both regimens provide a high
RDI, a worthwhile goal for patients receiving adjuvant chemotherapy
for breast cancer. This high RDI was achieved without need for
G-CSF, and infectious events were rare in spite of the absence of
prophylactic antibiotherapy. Using these regimens, the ANC
recovery was always observed after about 3 weeks, without any
risk of long-lasting neutropaenia. In our opinion, there is no
justification for the historical threshold ANC of 1.5 10
9l
 1 for
administration of adjuvant chemotherapy.
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